New Two-Pronged attack tested against rare cancers before surgery
NCT ID NCT04420975
Summary
This early-stage study is testing the safety of combining two immunotherapy drugs, nivolumab and BO-112, given before surgery for patients with operable soft tissue sarcoma. The goal is to see if stimulating the immune system to attack the tumor before it is removed can improve outcomes. The study will enroll about 14 patients to check for side effects and see how the treatment affects the tumor's immune environment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.